Noninvasive assessment of cancer response to therapy

Zhaozhong Han; Allie Fu; Hailun Wang; Roberto Diaz; Ling Geng; Halina Onishko; Dennis E. Hallahan

doi:10.1038/nm1691

Noninvasive assessment of cancer response to therapy

Zhaozhong Han, Allie Fu, Hailun Wang, Roberto Diaz, Ling Geng, Halina Onishko, Dennis E. Hallahan

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.

Original language	English
Pages (from-to)	343-349
Number of pages	7
Journal	Nature medicine
Volume	14
Issue number	3
DOIs	https://doi.org/10.1038/nm1691
State	Published - Mar 2008

Access to Document

10.1038/nm1691

Cite this

@article{959c8ae434c644df83f708e6f3fe952b,

title = "Noninvasive assessment of cancer response to therapy",

abstract = "Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.",

author = "Zhaozhong Han and Allie Fu and Hailun Wang and Roberto Diaz and Ling Geng and Halina Onishko and Hallahan, {Dennis E.}",

note = "Funding Information: This work was supported by US National Cancer Institute grants R01-CA89674, R01-CA112385 and R01-CA125757 (D.E.H.) and the Ingram Charitable Fund and the Vanderbilt-Ingram Cancer Center. We thank E. Ruoslahti (Burnham Institute) for the gift of T7 phage–based random peptide library and A. Kraker and P. Bailey (Pfizer) for technical assistance with mouse models of cancer.",

year = "2008",

month = mar,

doi = "10.1038/nm1691",

language = "English",

volume = "14",

pages = "343--349",

journal = "Nature Medicine",

issn = "1078-8956",

number = "3",

}

TY - JOUR

T1 - Noninvasive assessment of cancer response to therapy

AU - Han, Zhaozhong

AU - Fu, Allie

AU - Wang, Hailun

AU - Diaz, Roberto

AU - Geng, Ling

AU - Onishko, Halina

AU - Hallahan, Dennis E.

N1 - Funding Information: This work was supported by US National Cancer Institute grants R01-CA89674, R01-CA112385 and R01-CA125757 (D.E.H.) and the Ingram Charitable Fund and the Vanderbilt-Ingram Cancer Center. We thank E. Ruoslahti (Burnham Institute) for the gift of T7 phage–based random peptide library and A. Kraker and P. Bailey (Pfizer) for technical assistance with mouse models of cancer.

PY - 2008/3

Y1 - 2008/3

N2 - Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.

AB - Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=40449108294&partnerID=8YFLogxK

U2 - 10.1038/nm1691

DO - 10.1038/nm1691

M3 - Article

C2 - 18297085

AN - SCOPUS:40449108294

SN - 1078-8956

VL - 14

SP - 343

EP - 349

JO - Nature Medicine

JF - Nature Medicine

IS - 3

ER -

Noninvasive assessment of cancer response to therapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this